GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Revenue per Share

MDXXF (Pharmala Biotech Holdings) Revenue per Share : $0.01 (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Revenue per Share?

Pharmala Biotech Holdings's revenue per share for the three months ended in Feb. 2024 was $0.00. Pharmala Biotech Holdings's revenue per share for the trailing twelve months (TTM) ended in Feb. 2024 was $0.01.

During the past 12 months, the average Revenue Per Share Growth Rate of Pharmala Biotech Holdings was 650.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Pharmala Biotech Holdings's Revenue per Share or its related term are showing as below:

MDXXF's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Pharmala Biotech Holdings Revenue per Share Historical Data

The historical data trend for Pharmala Biotech Holdings's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Revenue per Share Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
Revenue per Share
- - 0.01

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of Pharmala Biotech Holdings's Revenue per Share

For the Biotechnology subindustry, Pharmala Biotech Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's PS Ratio falls into.



Pharmala Biotech Holdings Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Pharmala Biotech Holdings's Revenue Per Share for the fiscal year that ended in Aug. 2023 is calculated as

Revenue Per Share (A: Aug. 2023 )=Revenue (A: Aug. 2023 )/Shares Outstanding (Diluted Average) (A: Aug. 2023 )
=0.395/84.527
=0.00

Pharmala Biotech Holdings's Revenue Per Share for the quarter that ended in Feb. 2024 is calculated as

Revenue Per Share (Q: Feb. 2024 )=Revenue (Q: Feb. 2024 )/Shares Outstanding (Diluted Average) (Q: Feb. 2024 )
=0.067/86.908
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings  (OTCPK:MDXXF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Pharmala Biotech Holdings Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.